TCR1188-ABC Cells in KRAS-mutated Cancers

This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma, cholangiocarcinoma, colorectal cancer, or non-small cell lung cancer (NSCLC) will be targeted for participation. Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.

NCT Number	NCT07594067
Lead Sponsor	University of Pennsylvania Collaborators: National Cancer Institute (NCI)
Conditions	Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma
Enrollment	30 participants
Start Date	2026-08
Primary Completion	2042-07 (estimated)
Study Completion	2042-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-06